BOSTON – (May 13, 2014) – Joslin Diabetes Center announced today that Lori Laffel, M.D., M.P.H., Chief of the Pediatric, Adolescent and Young Adult Section at Joslin and Associate Professor of Pediatrics at Harvard Medical School, and Howard Wolpert, M.D., Director of the Joslin Institute for Technology Translation (JITT) and Associate Professor of Medicine at Harvard Medical School, will be honored as Research Champions at the JDRF’s upcoming Boston Gala. They will receive the Nancy Jones Diabetes Champion Award for Research at the 32nd Annual Boston Gala on May 17, 2014 at the Boston Marriott Copley Place. 

The Gala recognizes individuals who advocate for and have made contributions towards finding a cure for type 1 diabetes. Dr. Laffel and Dr. Wolpert are being honored for their many years of work in diabetes research at Joslin.

“I am honored to receive this award and am grateful to the JDRF for their tireless efforts to fund research aimed at advancing approaches to finding a biologic or technologic cure for diabetes, preventing acute and chronic diabetes complications, and improving care for persons with type 1 diabetes of all ages,” said Dr. Laffel.  

In addition to her role as Chief of Pediatrics at Joslin, Dr. Laffel is actively involved with the American Diabetes Association and is chair of both the Youth Strategies Committee and the Working Group on Transitions in Care for Type 1 Diabetes.

“It’s a great honor to be acknowledged by JDRF for the translational work of my group using technology to improve the lives of adults with type 1 diabetes. These emerging technologies have the potential to transform diabetes care as we know it,” said Dr. Wolpert.

Dr. Wolpert, in addition to serving as the Director of the JITT, is an Investigator in the Section on Clinical, Behavioral and Outcomes Research and Director of the Insulin Pump Program at Joslin. His research includes ways to best adopt technology for type 1 diabetes management. 

###

Related Articles

A Scientist working in lab
Type 1
Kidney Disease
Research Highlights

The Preventing Early Renal Loss in Diabetes (PERL) Study Conclusion

The Preventing Early Renal Loss in Diabetes (PERL) Study Conclusion

Three-year clinical trial finds reducing uric acid levels in type 1 diabetes provides no beneficial impact on the progression of diabetic kidney disease BOSTON – (November 8, 2019) – Diabetic kidney...
Read more on The Preventing Early Renal Loss in Diabetes (PERL) Study Conclusion
National Diabetes Month
Type 1
Type 2

National Diabetes Awareness Month

National Diabetes Awareness Month

Diabetes is growing at an epidemic rate in the United States and across the globe. According to the Centers for Disease Control and Prevention (CDC), over 30 million Americans have diabetes and 1.5...
Read more on National Diabetes Awareness Month
Red blood cell traveling in an artery
Type 1
Heart Disease
Research Highlights

Research may show way to minimize complications after heart treatment

Research may show way to minimize complications after heart treatment

BOSTON – (October 1, 2019) – People with diabetes are much more likely to develop heart disease than those without the condition. They also are several times more likely to develop complications after...
Read more on Research may show way to minimize complications after heart treatment